ANNUAL REPORT AND ACCOUNTS 2012

2

INTENTIONALLY BLANK

3

TABLE OF CONTENTS

2012 Summaries ··············································· 4 Chairman’s and Chief Executive’s Report ········· 6 Technology Platforms ······································· 9 Board of Directors and Officers ························ 11 Corporate Governance ····································· 12 Directors’ Report ·············································· 13 Compensation Report ······································· 15 Independent Auditors’ Report ·························· 16

4

Summaries

Operational Summary

As announced on 17 September 2012, the Company negotiated a multi‐year breathalyser distribution and supply agreement with Chubeworkx Guernsey Limited (“Chubeworkx”), the former Sono International Limited granting them an exclusive licence to market private‐labelled CHUBE breath alcohol detectors outside of North America in exchange for an upfront licence fee of $1,000,000; payment was initially conditional upon, inter alia, the breathalysers being deemed compliant with the French Standard, NF X 20‐702. The Company also began preparing the technical file in support of this certification.

Chubeworkx submitted a purchase order to ABI for 3.5 million CHUBE-branded, disposable Breath Alcohol Detectors with an order value of $1,050,000 in aggregate, and remitted $550,000 of the $1,000,000 licensing fee.

In late H1 2012, the Company’s breath alcohol detector technology was certified under AS 3547:1997, the Australian Standardsmark licence. The “5 ticks mark” for Breath alcohol testing devices for personal use clears the commercial pathway for product sales in Australia, New Zealand, South Africa, and many other countries through ABI’s distribution partner, UK-based (en)10 Guernsey Limited” (“(en)10”).

Forged a distribution relationship with Beijing‐based pharmaceutical and in vitro diagnostics marketer and supplier, Novotek Therapeutics Inc. (“Novotek”), for ABI’s Particle ImmunoFiltration Assay ("PIFA") products. The multi‐year agreement assigns exclusive sales and marketing rights for the products to Novotek in China.

The Company began shipping PIFA PLUSS PF4 rapid HIT Antibody point-of-care tests into the US market.

ABI completed $675,000 private equity raise through the sale of 30 million common shares and 10 million preferred.

Financial Summary

Total Revenue for 2012: $1.5 million (2011: $1.8 million)

Revenue for the Company’s Heparin/PF4 Rapid Assays totalled $1.12 million: (2011: $1.10 million)

Gross Profit Margin: 34.4% (2011: 49.9%)

Net Loss After Tax Benefit: $2.54 million (2011 loss: $3.58 million)

Earnings Before Interest, Depreciation, Taxes & Amortization (EBIDTA): loss $2.2 million (2011 loss: $3.3 million)

Basic & diluted loss per share: $0.01 (2011: $0.02)

Inventory at year end: $988k (2011: $685k)

Company is debt free with current assets in cash and cash equivalents at year-end of $633k (2011: $1.2 million)

Post Year-End Developments

The national reference laboratory of France, Laboratoire National de Métrologie et d'Essais (“LNE”), deemed the CHUBE private-labelled breathalyser to be in compliance with the quality criteria defined in French Standard NF X 20-702 for disposable breathalysers. This certification cleared that way for the CHUBE breathalyzers to be marketed by ABI’s UK based partner, (en)10, in and around

5

France. The issuance of the “NF Mark” triggered payment from Chubeworkx of the remaining $450,000 of the $1,000,000 licence fee established in Q3 2012.

The Company received the second order from Chubeworkx for 1.4 million disposable breath alcohol detectors, bringing the total order to-date under the distribution agreement to 4.9 million units. Within 9 months, these purchases surpassed the minimum quantities that Chubeworkx guaranteed to reach within a 3-year period.

On 13 June 2013, ABI announced the extension of the June 2012 License and Supply Agreement with Chubeworkx to include worldwide marketing and distribution of the CHUBE-branded detectors. Chubeworkx has agreed to subscribe for 80 million new common shares in the Company for a total price of $1,600,000. In addition, the parties have entered into a share purchase agreement in which ABI will sell its 20% interest in (en)10 to Chubeworkx for $100,000.

The Company and Novotek introduced the PIFA Heparin Platelet Factor 4 Rapid Assay to the Chinese market through a keynote address at the Annual Cardiac Disease Medical Conference in Beijing.

6

Chairman’s and Chief Executive’s Report The annual financial results for the Company, in US Dollars, for the year ended 31 December 2012 are presented within. Sales of the Heparin/PF4 Rapid Assays (PIFA and PIFA PLUSS) slightly increased in 2012. However, the growth in sales only picked up in the fourth quarter as the Company began to benefit from the strategy of its dedicated technical sales account executives moving away from a direct selling model to one that works in tandem with over 300 sales representatives of ABI’s US distribution partners, Cardinal Health (“Cardinal”) and Fisher HealthCare (“Fisher”). The good news is that this growth has continued into the current fiscal year. This strategy allows ABI to have immediate access to key laboratory and pathology decision makers in the majority of American cardiac hospitals and trauma centres. Surgical patients within these facilities are most at risk for developing Heparin-Induced Thrombocytopenia (“HIT”), a life- and limb-threatening complication of treatment with the blood thinner Heparin. Clinical HIT can be described as an allergy to this drug which reverses its intended therapeutic effect and causes blood clots. ABI’s assays continue to be the only FDA-cleared rapid, single-use tests available in the United States to screen for HIT; the PIFA straightforward test procedures can be completed 24/7 since specialized equipment and highly trained personnel are not required. Alternative testing methods rely on complex and time-consuming test procedures that are often run infrequently in hospitals or are sent out to reference laboratories. In both of these scenarios, reporting of test results is often delayed for 24-to-72 hours leaving a physician void of important patient information that cannot be factored into time-sensitive anticoagulation decisions. The Company’s ex-US presence for Heparin/PF4 Rapid Assays will begin to expand into Asia in 2013. As announced in Q4 2012, ABI signed an exclusive distribution agreement with Beijing-based, Novotek Therapeutics Inc. (“Novotek”). Novotek, a pharmaceutical and in vitro diagnostics marketer and supplier, is in the process of performing clinical studies to support its 2013 registration of the PIFA Heparin/PF4 Rapid Assay with regulatory authorities in China. Pre-selling activities have already commenced to build awareness of both the prevalence of Heparin-Induced Thrombocytopenia and the unique benefits of PIFA in providing a rapid HIT testing solution, with a formal product introduction at the Annual Chinese Cardiac Disease Medical Convention. Overall, sales of the PIFA Heparin/PF4 Rapid Assay, combined with the sales generated with the late Q4 launch of PIFA PLUSS PF4, contributed $1,120,000 to ABI’s total revenue for 2012. Sales of rapid tests that incorporate ABI’s MPC Biosensor breath condensate technology contributed to the remaining product revenue generated for 2012. The Company’s breath alcohol detectors marketed under the brand, BreathScan, together with private labeled versions of the disposable breathalysers, contributed $368,000 to ABI’s revenues. Much of ABI’s market share currently resides within the human resources (“HR”) testing sector. Given the longevity of the BreathScan trade name, some corporate SOPs identify the Company’s product by name and therefore have kept sales relatively consistent. However, lower-priced, lower-quality disposable Breath Alcohol detectors began infiltrating the HR market in 2012 which led to an approximate 17% decrease in breathalyser revenue as compared to 2011. As is evident from the Company’s numerous 2012 and 2013 announcements, growth in ABI’s breath alcohol detection business is moving away from a major concentration in HR toward a strategic focus on alcohol safety on a much broader, consumer-based level. To facilitate this shift, the Company has developed a global partnership with Chubeworkx Guernsey Ltd., a progressive sales and marketing organization that has the resources and market presence to aggressively pursue the much larger target audience for breathalysers through branding and innovative social media campaigns. The “BE CHUBE”

7

initiative (www.bechube.com) was launched Q1 2013 in France to support the launch of “NF-Marked” CHUBE breath alcohol detectors. The French Standard, NF X 20‐702 defines the specifications that chemical breath alcohol detectors must meet in order to be sold to consumers in France; CHUBE is one of four disposable products that have been certified by France’s national reference laboratory, Laboratoire National de Métrologie et d'Essais (“LNE”) to meet this stringent performance criteria. As of March 2013, a 2012 law took effect mandating that French motorists equip their vehicles with two, “NF‐Marked” breath alcohol detectors. As announced on 10 April 2013, Chubeworkx has already ordered 4.9 million CHUBE tubes to support their European campaign. The product is also already certified to be in compliance with the Australian AS-3547 standard, and as of 13 June 2013, ABI revised its Licence and Supply agreement with Chubeworkx to extend their reach into North America. As a result, the Company is confident that further orders to support Chubeworkx global strategic plan will be forthcoming. As reported, a cash advance of $550,000 was received in 2012 and the issuance of the “NF Mark” triggered payment from Chubeworkx of the remaining $450,000 of the $1,000,000 licence fee established in Q3 2012. The revenue was to be spread over the three years on the contract with $ 27,778 being booked in licencing revenue in 2012. With the minimum order amount having been exceeded already in 2013, the remaining $ 972,222 of the $1,000,000 licencing fee will be booked in H1 2013. In addition to breath alcohol detectors, the Company’s MPC Biosensor technology is being applied to the development of products that serve the nutraceutical and weight loss marketplaces. Biomarkers related to various metabolic processes can be measured in breath condensate. As a result, ABI has used its proprietary, easy-to-use platform to design disposable breath tubes that measure ketone production associated with fat-burning (METRON) and oxidative stress levels that relate to cellular damage and the development of many preventable diseases (VIVO). These products are now in full commercialization and the Company is currently assessing distribution opportunities with companies specializing in medically-assisted weight loss and/or mass distribution through health-related multilevel marketing organizations. Revenue for 2012 totalled $1,500,000 with a Gross Profit Margin of 34.4%. Both of these numbers are disappointing and the Board anticipates significant improvements in 2013 through revenues resulting from the new distribution agreements being put into place and an improvement in gross profit margin through absorption of underutilized manufacturing overhead. Expenditures related to the Company’s Research and Development activities increased by approximately 3% in comparison to those of 2011 (2012: $717,000 (2011: $698,000)). This is largely due to the development work related to:

the customization of ABI’s .05% breath alcohol detector to meet the very specific performance criteria of the French Standard, NF X 20‐702;

locking in the design of the emerging MPC-based VIVO oxidative stress, single-use analysers; and

the refinement of the METRON test to detect ketone levels associated with weight loss. ABI’s sales and marketing expenses decreased from the prior year (2012: $638,000 (2011: $707,000)) as management streamlined the Company’s sales model to include fewer technical sales professionals. As previously mentioned, the ABI account executive team began to work collaboratively with both Cardinal and Fisher outside sales representatives in 2012. As result, synergies in territory composition made some sales positions obsolete and allowed the Company to maintain national coverage with less head count by the end of Q3 2012.

8

ABI’s net loss after tax benefit is $2.54 million (2011 loss: $3.58 million) and basic & diluted loss per share is $0.01 (2011 loss: $.02). The total value of inventory held by the Company at 31 December 2012 was $988k (2011: $685k)). Outlook For 2013, ABI has already demonstrated that its strategic move toward alcohol safety initiatives within the aggregate consumer marketplace is a model that should bode favourably for the Company and its shareholders. The Chubeworkx partnership provides ABI with a sole source manufacturing demand pipeline for breath alcohol detectors and may also open up international markets for the Company’s PIFA rapid infectious disease products given Chubeworkx strong ties to Asia and Africa. ABI is dedicated to growing its Heparin/PF4 Rapid Assay global market share - in the United States through a collaborative sales approach that pairs ABI’s technical sales team with the depth of the Company’s national distribution sales forces, and internationally through agreements with specialized, well-established medical device companies. ABI is excited at the prospect of entering the nutraceutical market with a line of breath condensate detectors that can serve as companion tests to monitor progress with medically-assisted weight loss and health-and-wellness programs. Finally, the Company will be proceeding with clinical trials to support FDA 510(k) submissions for various rapid, breath condensate screening tests including the Breath Ketone “Check” test for diabetic screenings for ketoacidosis and the Breath PulmoHealth “Check” suite of products for Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer. The Directors believe that the continuing improvement in the Company’s commercial prospects is not reflected in its current share price and that this has a detrimental impact on the Company’s options for growth. The Directors are reviewing a number of alternatives designed to rapidly improve the situation. Thomas A. Nicolette, President and Chief Executive Officer Raymond F. Akers, Jr. PhD, Executive Chairman of the Board 26 June 2013

9

Technology Platforms ABI’s proprietary platform technologies merge scientific innovation with user-friendly formats to deliver cost-effective and time-efficient diagnostic testing and sample preparation solutions where and when they are needed. Diagnostic Testing Technologies Particle ImmunoFiltration Assay (PIFA®) Technology PIFA® technology is an accurate, rapid, immunoassay method based on the selective filtration of dyed microparticles coated with antigen or antibody. The microparticles are combined with a test sample (whole blood, serum, urine or saliva) within a self-contained device. If a patient tests positive for the antibody or antigen, a binding event will occur and the dyed microparticles will be trapped by a filter within the device. As a result, the test window will be void of any color. Conversely, if the patient tests negative, the dyed microparticles will flow freely into the test window. In short, Color in the test window = Negative; No Color = Positive. PIFA® Technology is currently protected by two United States Patents and one International Patent; an additional US Patent and one International Patent are pending. MPC Biosensor Technology MicroParticle Catalyzed Biosensor (MPC Biosensor) Technology permits the rapid identification of medical conditions through biomarkers in exhaled breath. These products contain microparticles that change color when a subject has a positive test result. The microparticles are coated with recently discovered agents that both decrease the time to result and provide a more defined color change when appropriate. MPC Biosensor-based products are packaged in small, disposable tubes through which test subjects can easily blow for several seconds. In the United States, the MPC Biosensor Technology is protected by two Patents, with an additional Patent pending. SMC Technology Synthetic Macrocycle Complex (SMC) Technology is a colorimetric testing methodology that pairs a proprietary reagent with a hand-held, photometric reader that determines the quantitative level of a therapeutic drug in a patient’s blood sample. The technology also permits the use of whole blood samples collected from a simple finger stick, making products that use this technology extremely flexible within the healthcare delivery system. Rapid Enzymatic Assay Rapid Enzymatic Assay (REA) technology enables the rapid detection of metabolites in blood and urine in assay formats that are easy-to-use and deliver quantitative or semi-quantitative results. Products that employ REA technology are primarily intended for pharmaceutical, nutritional and over-the-counter (OTC) markets. ABI has two United States Patents for this technology. minDNA™ Technology minDNA™ technology facilitates the analysis of DNA, in one minute, by a hand-held photometric reader. A mixture consisting of a patient’s whole blood specimen and a disposable reagent is exposed to the minDNAnalyzer, a digital hand-held reflectance photometer. These assays can be utilized at the point of care setting by non-clinical laboratory personnel using finger stick blood samples, or in the laboratory using EDTA whole blood specimens obtained through venous blood draws. This technology can be applied to the development of rapid white blood cell count and absolute neutrophil count assays that can monitor side effects of certain psychiatric and oncology drugs.

10

Sample Preparation Technology Rapid Blood Cell Separation Technology In addition to the Company’s testing platforms, ABI’s recently patented Rapid Blood Cell Separation (“Separator”) Technology, marketed under the brand name seraSTAT®, further accelerates the rate at which a test result is obtained as the often-required specimen preparation step is abbreviated drastically. Conventional methods of blood cell separation are labour-intensive and time-consuming, typically involving blood collection and laboratory personnel, as well as electrically-powered centrifuges and other specialized equipment. The Separator device only requires a small-volume blood sample obtained from a time- and cost-efficient finger stick procedure. The required micro-volume specimen of serum or plasma is immediately extracted and introduced into a rapid assay device for real-time analysis. The savings afforded by the Separator device can be measured in hours and dollars given its quick turn-around-time and straightforward, easy-to-master procedure. The Separator Technology is currently protected by two United States Patents and one International Patent.

11

Board of Directors and Officers

Board of Directors Raymond F. Akers Jr. PhD Executive Chairman of the Board Dr. Akers, co-founder of the Company in 1989, was named chairman in December 2009. He has over 26 years of experience in the diagnostics industry having co-founded Drug Screening Systems, Inc., a publicly listed company, in 1987 and Akers Medical Technology Inc. in 1984. He was chief executive officer and vice president of research and development of Drug Screening Systems, Inc. until the sale of the company in 1989 and served as president and chief executive officer of Akers Medical Technology Inc. until 1987. Dr. Akers holds a Ph.D. in Neurochemistry from Northwestern University, and is the inventor of the Company’s technology platforms. Thomas A. Nicolette President and Chief Executive Officer Mr. Nicolette, who started as a consultant to the Company, was elected a member of the Board in May 2006. Since 2000 he has served as principle of Nicolette Consulting Group Limited. In that role, Mr. Nicolette has been an officer and/or director of companies in the USA, Canada, Mexico, UK, France and Germany. Prior, he has served as Chief Executive Officer of several US based public companies. The largest, KNOGO Corporation, was a NYSE listed multinational company with subsidiaries and manufacturing facilities in 42 countries around the world employing over 4,000 people. KNOGO, recognized as the founder of the Electronic Article Surveillance (EAS) anti-shoplifting industry, was sold to Sensormatic Electronics in 1994 and is now part of Tyco International’s ADT Security. Mr. Nicolette is a graduate of Michigan State University School of Criminal Justice. Edward Mulhare Former Non‐Executive Director, deceased 24 February 2012 Mr. Mulhare joined the Board in April 1994. He served as the chairman of the board of SenTech EAS Corporation since May 1994. Over the past ten years, he served as a director of fifteen companies including Aldila Inc., Truck Components, Inc., Pan American Diamond Co., McGraw Industries, Inc., and American Silver Co. Mr. Mulhare served as the chairman of the board and chief executive officer of Merrill Lynch Interfunding, Inc., which managed a $1.6 billion leveraged acquisition portfolio. In addition, he has served as executive vice president of Republic National Bank of New York and vice president of Prudential Insurance Company.

Officers Patrice Laterra McMorrow Vice President Marketing Ms. McMorrow has 25 years of experience in sales and marketing within the medical device, pharmaceutical, ophthalmic eyewear and fashion industries. Competencies include strategic and tactical planning and implementation, sales training and operations, and distribution management. Ms. McMorrow holds an MBA with a concentration in marketing from Seton Hall University. Gary M. Rauch Financial Controller Mr. Rauch has over 30 years of Accounting, Information Systems and Operations Consulting experience in a variety of industries including healthcare, manufacturing and distribution. Mr. Rauch holds a degree in Accounting from the University of South Carolina.

12

Board of Directors and Officers

Corporate Governance Companies that have securities traded on the Alternative Investment Market (AIM) are not required to comply with the disclosures of the Combined Code. However the Board is committed to maintaining high standards of corporate governance.

Board of Directors For 2012, the Company was controlled by the Board of Directors which was initially comprised of two executive and one non-executive Directors. On 24 February 2012, the Board’s non-executive Director, Edward Mulhare, passed away. Currently the Board consists of two executive Directors. All Directors were and are able to take independent financial advice in furtherance of their duties if necessary. The Board is responsible to shareholders for the proper management of the Company and meets formally at least four times a year to set the overall direction and strategy of the Company, to review financial and operating performances and to advise on senior management appointments. Financial policy and budgets, including capital expenditure, are approved and monitored by the Board. All key operational decisions are subject to Board approval. The Company Secretary is responsible for ensuring that Board procedures are followed and that applicable rules and regulations are complied with. Directors are subject to election by shareholders at the first opportunity after their appointment.

Relations with Shareholders The Board attaches great importance to effective communication with shareholders and encourages dialogue with both its institutional and private investors and responds promptly to all questions received orally or in writing. Directors attend meetings with analysts and institutional shareholders throughout the year. All shareholders have at least 10 days notice of the Annual General Meeting at which they have the opportunity to discuss the Company’s developments and performance. In compliance with the requirements set out under Rule 26 of the AIM Rules, the Company operates a website which can be found at www.akersbiosciences.com. It contains further details of the Company and its activities.

13

Directors’ Report The Directors who served during the year, together with their beneficial interest in the common shares (no par value) of the Company as of 31 December 2012, are as follows:

Executive

Raymond F. Akers, Jr.1 Executive Chairman 8,824,338 Thomas A. Nicolette President and CEO 6,000,538

Non-Executive

Edward Mulhare2

1,936,415

1 Included in the amount of shares shown for Dr. Akers are 115,000 common shares which are held by The Akers Family Foundation, of which Dr. Akers is the trustee and 2,425,866 shares held by his mother, Delores Akers.

2 Included in the amount of shares shown for Edward Mulhare are 136,444 shares held by his wife.

Share Capital Information relating to shares issued in the financial period is given in the accompanying Consolidated Statements of Changes in Equity (Deficiency) (page 19).

Auditors For the year ended 31 December 2012, Morison Cogen LLP served as the Company’s auditors.

Substantial Shareholdings As of December 31, 2012, the following shareholders were registered as being interested in 3% or more of the Company’s common shares outstanding: Shareholder Name Number of

Common Shares Held Percent (%)

Thomas J. Knox1 30,000,000 15.09% Legal & General Group plc 28,035,000 14.10% John Harvey 13,850,000 6.97% Commerzbank AG 8,728,500 4.39% Saltburn Limited 8,321,023 4.19% Raymond F. Akers, Jr2 8,824,338 4.44% Thomas A. Nicolette 6,000,538 3.02%

1 Mr. Knox also holds 10,000,000 preferred shares that are convertible, at any time, into common shares, at the rate of 5 common shares

for each preferred share for an additional payment of $0.05 per converted preferred share. While holding the preferred, he has the right to vote at a rate of 5 votes per preferred share.

2 Included in the amount of shares shown for Dr. Akers are 115,000 common shares which are held by The Akers Family Foundation, of

which Dr. Akers is the trustee and 2,425,866 shares held by his mother, Delores Akers.

14

Remuneration Policy for Executive Directors The remuneration policy has been designed to ensure that executive Directors should receive appropriate incentive and reward given their performance, responsibility and experience. In determining this, the Remuneration Committee has regard to ensure that the policy aligns the interests of executive Directors with those of the shareholders. The Company’s remuneration policy for executive Directors is to:

Have regard to the individual’s experience and the nature and complexity of their work in order to pay a competitive salary that attracts and retains management of the highest quality, while avoiding remunerating those Directors more than is necessary.

Link individual remuneration packages to the Company’s long-term performance through the award of share options and bonus schemes.

Provide employment related benefits including the provision of life assurance and medical insurance.

Remuneration Policy for Non-Executive Directors The remuneration of the non-executive Directors is determined by the Board as a whole, based on a review of current practices in other equivalent companies. Prior to his passing, Non-executive Director Edward Mulhare, did not receive any consulting fee, pension or other benefits from the Company in 2012.

15

Compensation Report The Directors earned the following remuneration during the year:

Name of Director Salary & Fees Taxable Benefits Totals 2012 2011 Executive Raymond F. Akers, Jr.1 $350,000 $7,800 $357,800 $353,085 Thomas A. Nicolette2 $335,004 $- $335,004 $333,506 Non-Executive Edward Mulhare $- $- $- $40,000 1 Dr. Akers’ employment agreement was renegotiated on 12 January 2011. The company is required to pay an annual salary of $350,000. He is entitled

to participate in all bonus, incentive compensation plans and employee benefit programs made available to executive officers of the company. The contract may be terminated by either party at any time prior to the expiration of the contract. If the contract is terminated by the Company other than for cause as defined in the contract, the Company is obligated to pay Dr. Akers a severance and non-competition payment. In the event that Dr.

Akers terminates the contract, he shall receive his base salary for the month in which the termination occurs. Dr. Akers agrees that any new inventions and improvements made to existing intellectual property in the course of his employment shall be assigned to and be the sole property of the Company.

2 Mr. Nicolette’s 2012 Compensation is detailed within Note 19 (page 42)

Aggregate emoluments disclosed above do not include any amounts for the value of options or warrants to acquire common shares in the Company granted to or held by the Directors. Details of the options and warrants are as follows:

Name of Director

As of 31 December 2012

Exercise Price ($)

Date of Expiry

Executive Raymond F. Akers, Jr. 3,500,000 0.18 - 0.32 8/1/2017 – 8/1/2019 Thomas A. Nicolette 3,500,000 0.18 - 0.32 28/9/2017 – 8/1/2019

Directors’ Shareholdings This information may be found within the Directors’ Report (page 13).

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Company Information At-A-Glance

Ticker Symbols AKR AKR.L Corporate Offices 201 Grove Road Thorofare, New Jersey 08086 USA 1.800.451.TEST (8378) + 1 856.848.8698 180 Piccadilly London, W1J 9HG UNITED KINGDOM + 44 (0)20 7917 9476 www.akersbiosciences.com Email: info@akersbiosciences.com

Nominated Adviser & Broker Daniel Stewart & Company Plc Becket House 36 Old Jewry London EC2R 8DD UNITED KINGDOM + 44(0) 20 7776 6550 www.danielstewart.co.uk Auditors Morison Cogen LLP 150 Monument Road Suite 500 Bala Cynwyd, Pennsylvania 19004 USA + 1.267.440.3000 www.morisoncogen.com

Attorneys Lucosky Brookman 101 Wood Avenue South Woodbridge, New Jersey 08830 USA +1.732.395.4400 http://lucbro.com/ Transfer Agent Capita Registrars The Registry 34 Beckingham Road Beckingham, Kent BR3 4TU UNITED KINGDOM + 44 (0)208 639 2157 www.capitaregistrars.com

www.akersbiosicences.com